Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
3 Incredible Growth Stocks to Buy if the Market Dips
03:45pm, Thursday, 02'nd Mar 2023 The Motley Fool
These top growth stocks sport premium valuations for a very good reason.
2 Surging Healthcare Stocks That Are Still Worth Buying
03:30pm, Thursday, 23'rd Feb 2023 The Motley Fool
These two NASH drugmakers have a lot of room to run.
Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval
02:43pm, Wednesday, 15'th Feb 2023 MarketWatch
Madrigal Pharmaceuticals' resmetirom is a leading treatment candidate for the advanced form of fatty liver disease.
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
01:00pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepa
This "Golden" Technical Indicator is Triggering Across the Market
01:36pm, Thursday, 26'th Jan 2023 Zacks Investment Research
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
This "Golden" Technical Indicator is Triggering Across the Market
09:47am, Thursday, 26'th Jan 2023
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
02:53pm, Friday, 20'th Jan 2023 Zacks Investment Research
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
10:53pm, Thursday, 19'th Jan 2023
Mid-cap stocks are proving to be an attractive investment option over the past few years.
Madrigal: Fairly Valued At These Levels
02:35pm, Tuesday, 17'th Jan 2023
As everyone knows, Madrigal outperformed expectations with outstanding results stemming from Maestro NASH study. I assess Madrigal's current valuation, based on future sales potential of resmetirom in
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
04:41pm, Friday, 13'th Jan 2023 Zacks Investment Research
Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.
3 Top Healthcare Stocks to Buy for January
10:52am, Wednesday, 11'th Jan 2023 The Motley Fool
These healthcare stocks have a lot going for them in the new year.
3 Top Healthcare Stocks to Buy for January
05:52am, Wednesday, 11'th Jan 2023
These healthcare stocks have a lot going for them in the new year.
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
10:50pm, Monday, 09'th Jan 2023
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
01:00pm, Friday, 06'th Jan 2023 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepat
Traders who bet against stocks made a killing in 2022, as short sellers netted $300 billion
08:35pm, Thursday, 05'th Jan 2023
Short holdings had a return of 30.8% in 2022 as the market slid.
